Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;40(3):465-473.
doi: 10.1007/s12928-025-01126-5. Epub 2025 Apr 5.

Pericoronary adipose tissue: potential for pathological diagnosis and therapeutic applications

Tomoya Hara  1 , Masataka Sata  2
Affiliations
Review

Pericoronary adipose tissue: potential for pathological diagnosis and therapeutic applications

Tomoya Hara et al. Cardiovasc Interv Ther. 2025 Jul.

Abstract

Excessive accumulation of epicardial adipose tissue (EAT) is known to be a risk factor for coronary artery disease and heart failure. In particular, it is thought that inflammation of pericoronary adipose tissue (PCAT) affects the pathology of various coronary artery diseases (CAD). EAT and PCAT are thought to be new therapeutic targets for preventing cardiovascular disease. Although there are no established drugs that specifically reduce inflammation of EAT or PCAT, the basic approach is to improve lifestyle-related diseases through exercise and diet, and to use metabolic improvement drugs and anti-inflammatory drugs as soft support. Potential candidates include statins, SGLT2 inhibitors, and GLP- 1 receptor agonists. In addition to conventional treatments that target substances within blood vessels, treatments that target EAT and PCAT by directly enveloping the coronary arteries and myocardium from outside the body are expected to further suppress cardiovascular events.

Keywords: Atherosclerosis; Chronic inflammation; Coronary artery diseases (CAD); Epicardial adipose tissue (EAT); Pericoronary adipose tissue (PCAT); Perivascular adipose tissue (PVAT); Vasa vasorum (VV).

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that this study was conducted and described in the absence of any commercial or financial relationships that could be considered a potential conflict of interest.

References

    1. Akoumianakis I, Tarun A, Antoniades C. Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets. Br J Pharmacol. 2017;174:3411–24. https://doi.org/10.1111/bph.13666 . - DOI - PubMed
    1. Tanaka K, Fukuda D, Sata M. Roles of epicardial adipose tissue in the pathogenesis of coronary atherosclerosis—an update on recent findings. Circ J. 2020;85:2–8. https://doi.org/10.1253/circj.CJ-20-0935 . - DOI - PubMed
    1. Wang M, Pan W, Xu Y, Zhang J, Wan J, Jiang H. Microglia-mediated neuroinflammation: a potential target for the treatment of cardiovascular diseases. J Inflamm Res. 2022;15:3083–94. https://doi.org/10.2147/jir.S350109 . - DOI - PubMed - PMC
    1. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33. https://doi.org/10.1161/01.Atv.0000099786.99623.Ef . - DOI - PubMed
    1. Antoniades C, Tousoulis D, Vavlukis M, Fleming I, Duncker DJ, Eringa E, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur Heart J. 2023;44:3827–44. https://doi.org/10.1093/eurheartj/ehad484 . - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources